Search
Temocapril
go.drugbank.com/drugs/DB08836InvestigationalTemocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea. … Temocapril can also be used in hemodialysis patients without risk of serious accumulation.
Categories: Agents Acting on the Renin-Angiotensin System, Heterocyclic Compounds, 1-RingLubiprostone
go.drugbank.com/drugs/DB01046ApprovedInvestigationalA prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastrointestinal epithelial cells. … Lubiprostone is a medication used in the management of idiopathic chronic constipation.
Categories: Prostaglandins EProducts: MOVIPROST ® 8 MCG, อามิทีซา 8 ไมโครกรัมSonrotoclax
go.drugbank.com/drugs/DB18753ApprovedInvestigationalIt is the first BCL-2 inhibitor approved for MCL and the second oncology-approved BCL-2 inhibitor overall, following venetoclax. … [L56193,A275521] Sonrotoclax was rationally designed as a BH3 mimetic with a shallow and broad interaction with the P2 pocket of BCL-2, achieved through a novel 7-azaspiro[3.5]nonane linker; this binding
Categories: BCL-2 Inhibitor, P-glycoprotein substratesSynonyms: N-[4-({[(1r,4r)-4-hydroxy-4-methylcyclohexyl]methyl}amino)-3- nitrobenzene-1-sulfonyl]-4-(2-{(2S)-2-[2-(propan-2-yl)phenyl]pyrrolidin- 1-yl}-7-azaspiro[3.5]nonan-7-yl)-2-[(1H-pyrrolo[2,3-b]pyridin-5- ylZinc citrate
go.drugbank.com/drugs/DB11154ApprovedInvestigationalZinc citrate is a zinc salt of citric acid. It is available as dietary supplements as a treatment of zinc deficiency and source of zinc, which is an essential trace element.
Mixtures: Vitamin A C E W.niacinam.beta Car.and Min., Cal-mag (one To One) With Potass & ZincVepdegestrant
go.drugbank.com/drugs/DB19006ApprovedInvestigational[A275508, A275509] On May 1, 2026, the FDA granted approval for vepdegestrant tablets under the trade name VEPPANU. … [A275507, A275509] It serves as an advanced option to address the clinical challenge of endocrine-resistant breast cancer subtypes.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2B6 InhibitorsSynonyms: 2,6-piperidinedione, 3-(1,3-dihydro-1-oxo-5-(4-((1-(4-((1r,2s)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl)phenyl)-4-piperidinyl)methyl)-1-piperazinyl)-2h-isoindol-2-yl)-, (3s)-Triclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigational[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola … Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesStannous chloride
go.drugbank.com/drugs/DB11056ApprovedTin reduces technetium-99m, the active radiological agent, allowing it to form a complex with phosphate-containing moeities [A32700]. … Stannous chloride is used as a source of tin in radiopharmaceutical kits.
Cosibelimab
go.drugbank.com/drugs/DB15770ApprovedInvestigationalOn December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the … Cosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1).
Categories: Programmed Death Ligand-1 Blocker, Programmed Death Receptor-1 Blocking AntibodySynonyms: IMMUNOGLOBULIN G1-LAMBDA, ANTI-(HOMO SAPIENS PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1, CD274 ANTIGEN))HUMAN MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-450) (HOMO SAPIENS VH (IGHV1-69*01 (94%) (IGHD)-IGHJ1, *01) (8.8.13) (1-120)-HOMO SAPIENS IGHG1*01 (121-45Niclosamide
go.drugbank.com/drugs/DB06803ApprovedInvestigationalVet approvedNiclosamide is an antihelminthic used for the treatment of tapeworm infections. … Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.[L11860]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsProducts: TENYADÜŞ TABLET, 4 ADET, YOMESAN 500 MG TABLET, 4 ADET